Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Ex-FDA chief Robert Califf about HHS Secretary Robert F. Kennedy Jr. — “My primary worry is not the FDA, my worry is the ...

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...

The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine — the nation's only traditional protein-based option for the coronavirus — is sowing uncertainty about ...

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...

Vaccine maker Novavax is seeking to convert the 2022 emergency authorization of its Covid-19 vaccine into full approval. Yet ...

Novavax said on Thursday discussions with the U.S. health regulator on its COVID-19 shot are ongoing and a pathway to ...

After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

BofA Securities 2025 Health Care Conference May 14, 2025 6:00 PM ETCompany ParticipantsJohn Jacobs - President and CEOJim ...

Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year ...

(Reuters) - Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S. regulators saying that it sees a pathway to resolving issues with ...